Alpha Lifetech Inc. was founded by a group of scientists with extensive experience in membrane protein production, nanobody discovery, monoclonal development, and other pharmaceutical pre-development services. Based on our several technology service platforms, Alpha Lifetech Inc. has launched nearly 10,000 high-quality spot membrane protein reagents, cytokines, drug target antibodies and other related reagents. Whether you're working in the fields of immunology, cell biology, molecular biology, or any other scientific discipline, Alpha Lifetech's comprehensive range of research products will help you achieve accurate and reliable results. We pride ourselves on being able to offer a comprehensive set of high-quality products and services tailored to customer needs, which help advance the projects of scientific research institutions, academics, and enterprises in the life science industry.
Yeast display technology has emerged as one of the most powerful platforms for nanobody (VHH single-domain antibody) screening and engineering. By expressing nanobody libraries on the surface of Saccharomyces cerevisiae, researchers can leverage the eukaryotic protein folding machinery and FACS-based high-throughput sorting to rapidly identify binders with exceptional affinity and selectivity.
Unlike phage display, yeast display enables quantitative, fluorescence-activated cell sorting (FACS) of individual yeast cells displaying nanobodies, allowing precise selection based on binding affinity, kinetics, and specificity. The eukaryotic expression environment ensures proper disulfide bond formation and post-translational processing critical for functional VHH domains — making yeast display the gold standard for high-quality nanobody discovery pipelines.
Yeast cells provide a eukaryotic milieu that supports proper folding of VHH domains, ensuring functional display and authentic binding behavior of each nanobody candidate.
Flow cytometry sorting enables screening of libraries exceeding 108 variants in a single experiment, drastically shortening the discovery timeline compared to traditional panning approaches.
Iterative rounds of mutagenesis and FACS sorting allow progressive improvement of binding affinity, often achieving sub-nanomolar KD values for challenging therapeutic targets.
Competitive staining protocols enable selection of nanobodies targeting specific epitopes, facilitating the discovery of blocking, non-blocking, or biparatopic binders for complex targets.
Through tailored products, adaptable service and packaging choices, and unwavering support, Alpha Lifetech Inc. guarantees that researchers have access to the most fitting and efficient tools tailored to their research endeavors.
Our team of experienced scientists works closely with customers to design and execute tailored strategies for nanobody discovery using yeast display screening, ensuring the generation of high-quality leads that align with project goals.
Antibody humanization from a broad range of parental species including mouse, rat, rabbit, llama, and avian — fully compatible with yeast-display-derived nanobody leads.
Our Membrane Proteomics platform offers comprehensive solutions for identification, quantification, and characterization of membrane proteins — essential antigen targets for yeast display nanobody screening campaigns.
Alpha Lifetech can offer native antibody libraries (scFv, Fab, VHH formats and customized) from host animals like Goat, Camel and Llama — optimized for yeast surface display.
Our end-to-end yeast display nanobody service follows a rigorous, reproducible pipeline — from immunization to validated hits — ensuring maximum discovery success rates.
Camelid immunization with target antigen; VHH gene amplification and cloning into yeast display vector.
High-efficiency electroporation into S. cerevisiae; surface expression verification by flow cytometry.
Fluorescent antigen labeling; iterative FACS sorting for affinity enrichment across 3–5 rounds.
Individual clone sequencing, expression, and binding validation by ELISA, SPR, and BLI.
Purified nanobody hits with full characterization data, sequence files, and comprehensive project report.
Alpha Lifetech Inc. is committed to providing the highest level of customer services, competitive pricing, speedy delivery, and a comprehensive, cutting-edge product offering. Our sales and technical support staff are available to help you select the right products and service solutions. As a reliable supplier and partner, Alpha Lifetech Inc. always puts customers first. We cherish every opportunity to collaborate with worldwide customers in scientific exploration. Welcome to contact our technical support at any time.
Our years of manufacturing experience and refined products provide you with better protection.
The global nanobody market is projected to exceed USD 8 billion by 2030, driven by unprecedented demand in oncology, infectious disease, and industrial biotechnology. Yeast display screening is at the forefront of this revolution — enabling faster, smarter, and more cost-effective nanobody discovery pipelines.
With the approval of caplacizumab (the first nanobody drug) and a robust pipeline of VHH-based therapeutics in clinical trials, yeast display screening has become indispensable for identifying candidates against GPCRs, ion channels, and other intractable drug targets. The ability to screen against membrane-embedded antigens in near-native conformations makes yeast display uniquely suited for next-generation biologic drug discovery.
Nanobodies discovered via yeast display are increasingly deployed in lateral flow assays, ELISA kits, and biosensor platforms for point-of-care diagnostics. Their exceptional thermal stability, resistance to harsh conditions, and small size (15 kDa) enable multiplexed detection formats impossible with conventional IgGs — opening new commercial opportunities in food safety, environmental monitoring, and clinical diagnostics.
Conformationally selective nanobodies identified by yeast display serve as powerful chaperones for cryo-EM structure determination of flexible membrane proteins and protein complexes. This application has become a critical tool in structure-based drug design, with major pharmaceutical companies integrating yeast-display-derived nanobodies into their structural biology workflows.
VHH domains selected by yeast display are being incorporated into next-generation CAR-T constructs, offering reduced immunogenicity, superior tumor penetration, and the ability to target antigens inaccessible to conventional scFv-based CARs. Yeast display enables rapid optimization of the CAR nanobody domain for optimal tumor cell engagement and minimal off-target toxicity.
Beyond therapeutics, yeast-display-screened nanobodies are finding commercial applications as highly stable capture agents in industrial biosensors, protein purification affinity resins, and enzyme stabilization. Their compatibility with harsh industrial conditions (high temperature, extreme pH) makes them ideal for bioprocessing and environmental monitoring applications.
The convergence of yeast display screening data with AI/ML-driven antibody design platforms is transforming nanobody discovery. Large experimental datasets from FACS-sorted yeast libraries are being used to train deep learning models that predict binding affinity from sequence alone — dramatically accelerating the design-build-test cycle and enabling in silico pre-screening of billions of VHH variants.
Alpha Lifetech Inc. provides a wide range of technology platforms, including membrane protein, antibody discovery, single B cell sorting, and hybridoma technology. Whether you're engaged in immunology, cell biology, molecular biology, or any other scientific discipline, our comprehensive suite of services is designed to empower you with precise and dependable results.
Our platform utilizes phage and yeast display technology to develop different forms of antibodies: VHH single domain antibodies, Fab antibodies, and scFv antibodies, resulting in high affinity and high specificity antibodies. The yeast display component of our pipeline is particularly powerful for nanobody affinity maturation and epitope-specific selection against complex targets.
READ MORE
VHH Antibody Discovery Service
View Details
Fab Antibody Discovery Service
View Details
ScFv Antibody Discovery Service
View Details
Phage Display System
View Details
Phage Library Construction Service
View Details
Phage Display Screening Service
View DetailsThe aptamer platform provided by Alpha Lifetech includes two categories: aptamer synthesis platform, which mainly involves SELEX aptamer library synthesis service and aptamer development service, and aptamer screening platform including screening services based on SELEX technology for proteins, peptides, cells, small molecules, and other target molecules, as well as aptamer optimization and identification analysis services.
READ MORE
Aptamer Synthesis Platform
View Details
Aptamer Screening Platform
View Details
Aptamer Optimization Service
View Details
Aptamer Analysis Service
View Details
Aptamer Research Service
View Details
Our monoclonal antibody development services include three technologies: phage display technology, single-B cell technology, and hybridoma cell technology, which produce monoclonal antibodies for different species. Each platform is seamlessly integrated with our yeast display nanobody screening capabilities for comprehensive antibody engineering solutions.
READ MORE
Single B Cell Sorting Platform
View Details
Hybridoma Technology Platform
View Details
Phage Display Technology Platform
View Details
Mouse mAb Development Service
View Details
Rabbit mAb Development Service
View DetailsWe also provide a series of technical services related to antibody engineering, stable cell line construction, yeast display, protein interaction analysis, etc., laying the foundation for antibody development. Our dedicated yeast display library construction and screening services are specifically optimized for nanobody discovery campaigns, offering industry-leading library diversity and sorting throughput.
READ MORE
Stable Cell Line Construction Service
View Details
Animal Immunization Platform
View Details
Protein Interaction Service
View Details
Yeast Display Library Construction Service
View Details
Yeast Display Library Screening Service
View DetailsWhat our global partners say about Alpha Lifetech's nanobody and yeast display screening services.
Exceptional Nanobody discovery capabilities from Alpha Lifetech. Their team's dedication to customer satisfaction and scientific excellence is evident in every interaction. Grateful for their partnership and looking forward to future collaborations!
— Riley HarperQuality products! Our experience with Alpha Lifetech has been nothing short of outstanding. The yeast display screening results exceeded our expectations in both throughput and hit quality.
— Stella GrantReliable, responsive, and results-driven — Alpha Lifetech. Their yeast display nanobody service delivered high-affinity binders against our challenging membrane protein target within the agreed timeline.
— Olivia WestSimply put, Alpha Lifetech delivers. Their dedication to customer satisfaction and quality service is unmatched, and we're grateful to have them as a trusted partner in our nanobody discovery programs.
— Ava MitchellExplore our comprehensive portfolio of technology services that support and complement nanobody yeast display screening campaigns — from library construction to protein interaction analysis.
Stable Cell Line Construction Service for Yeast Display
View Details
Animal Immunization for Nanobody Library Generation
View Details
Protein Interaction Analysis for Nanobody Validation
View Details
Yeast Display Library Construction Service
View Details
Yeast Display Library Screening Service
View Details
Nanobody Affinity Maturation via Yeast Display
View Details
FACS-Based Single B Cell Sorting for Nanobody Discovery
View Details
VHH Nanobody Discovery & Yeast Display Screening
View Details